Activation of P38 MAPK leads to the activation of Nuclear factor erythroid 2-related factor 2 (Nrf2), thereby leading to the acquired drug resistance58 to temozolomide in glioma cells. This evidence concerns the gene NFE2L2 and central nervous system cancer.